Accelerating R&D to Commercialization by Leveraging Predictive Biomarkers & Clinical Diagnostics Evidence for Best Patient Outcomes in Target Populations
The 11th World Clinical Biomarkers & CD x Summit returns in 2021 as the only end-to-end industry-led meeting diving deep into the science of transitioning biomarkers to the clinic, their clinical validation and later commercialization with a CDx.
With the increasing sophistication of diagnostic processes and expanding knowledge about association between biomolecules, genomics and acute disease, interest in biomarkers is at an all-time high. As the industry is delivering significant patient benefits, accelerated clinical timelines and healthcare cost savings, now is the time to join with key stakeholders across biomarker, translational, clinical, regulatory and commercial functions to tackle end-to-end challenges and deliver game-changing drug-Dx products to market.
Across 2 days of comprehensive content, we will gather 1000+ precision medicine pioneers online as 70+ global expert speakers share inspiring stories, unpresented data and innovative partnership collaborations to help you overcome your most pressing challenges and accelerate curative medicine.
With three tracks, explore movement within bioanalytical analysis, AI/ML application, data sharing and the regulatory and payer landscape across immune-oncology, neurodegenerative, metabolic, autoimmune and rare indications for a diverse picture of today’s expanding personalized medicine ecosystem.
Join us for an unmissable event, brining you the tools, insights and techniques to design a clinically robust biomarker and commercially competitive CDx!
Returning to a three-tracked format, World CB & CDx is designed to be your organization’s one-stop-shop for end-to-end insights across the spectrum of precision medicines drug development.
Here’s what you can get involved in:
Your Plenary Speakers
Gathered by the aim of getting the best option to the right patient as quickly and efficiently as possible, unite with the 1000+ of your precision medicine peers to explore precision medicine opportunity to treat diverse populations, end-to-end CDx development case studies, latest diagnostic interventions reaching the market and biopharma’s efforts to maximise the utility of data.
Director, Companion Diagnostics Strategy Lead
Director, Translational Oncology
Vice President, Translational Biology
Senior Advisor & Executive Coach
The Boston Consulting Group (BCG)
Moving Biomarkers Towards the Clinic Speakers
Support your early biomarker discovery and development through robust analytical validation and effectively validate and translate assays to make the clinical transition. Meet leaders challenging complex disease heterogeneity across immune-oncology, metabolic, autoimmune and neurodegenerative disease with NGS, organoid modelling, multi-omics and comprehensive data collection.
Global CoDx Market Access Director
Senior Director, Regulatory Affairs (CDx)
Executive Director, Head of CDx Marketing (US) VITRAKVI
Senior Research Analyst for Medical Policy & Technology Evaluation
Independence Blue Cross
Director, Biomarker Sciences
Clinical Biomarker & Assay Development
Draw actionable insights from clinical data to establish an effective trial strategy and inform treatment decisions making an impact in target populations. Showcasing data from small molecules, T-cell therapies, bispecific antibodies and neoantigen studies, and featuring the latest on liquid biopsy and genomic analysis, determine your clinical cut-offs with confidence.
Chief Medical Officer
Chief Executive Officer, Chief Medical Officer
Head of CDx Cell & Gene Therapies Oncology
Director, Global Regulatory Affairs, Medical Devices
Senior Director of Immuno–Oncology
Pieris Pharmaceuticals GmbH
Develop, identify and validate the technologies you need to obtain optimal results from your trials then establish effective internal and external stakeholder collaboration to expedite drug-Dx commercialization whilst optimizing reimbursement. Apply expert practical knowledge to navigate the fast-growing CDx market delving into case studies across oncology in addition to emerging gene therapy and rare disease, and gain a picture of the real-world-evidence and patient perspectives broadening assay adoption.
Director, Pharmacology/ Translational Medicine
Associate Director & Head of Translational Genetics
Branch Chief, National Center for Toxicological Research
US Food & Drug Administration
Vice President, Head of Translational Medicine
President & Founder